2,160 Shares in Mirati Therapeutics Inc (NASDAQ:MRTX) Acquired by Pitcairn Co.

Pitcairn Co. bought a new position in Mirati Therapeutics Inc (NASDAQ:MRTX) in the second quarter, according to the company in its most recent 13F filing with the SEC. The fund bought 2,160 shares of the biotechnology company’s stock, valued at approximately $247,000.

Other large investors have also recently added to or reduced their stakes in the company. Advisor Group Holdings Inc. bought a new stake in Mirati Therapeutics in the 1st quarter worth approximately $28,000. Column Capital Advisors LLC lifted its position in Mirati Therapeutics by 27.4% in the 1st quarter. Column Capital Advisors LLC now owns 1,073 shares of the biotechnology company’s stock worth $82,000 after buying an additional 231 shares during the last quarter. First Mercantile Trust Co. lifted its position in Mirati Therapeutics by 18.4% in the 1st quarter. First Mercantile Trust Co. now owns 1,205 shares of the biotechnology company’s stock worth $93,000 after buying an additional 187 shares during the last quarter. Banque Cantonale Vaudoise bought a new stake in Mirati Therapeutics in the 1st quarter worth approximately $113,000. Finally, Zurcher Kantonalbank Zurich Cantonalbank lifted its position in Mirati Therapeutics by 9.4% in the 1st quarter. Zurcher Kantonalbank Zurich Cantonalbank now owns 2,115 shares of the biotechnology company’s stock worth $163,000 after buying an additional 182 shares during the last quarter.

A number of analysts recently weighed in on the company. Goldman Sachs Group assumed coverage on Mirati Therapeutics in a research report on Thursday, April 16th. They issued a “buy” rating and a $151.00 target price for the company. BidaskClub upgraded Mirati Therapeutics from a “hold” rating to a “buy” rating in a research report on Monday, July 20th. Credit Suisse Group boosted their price objective on Mirati Therapeutics from $115.00 to $135.00 and gave the company an “outperform” rating in a research report on Wednesday. Finally, JPMorgan Chase & Co. upgraded Mirati Therapeutics from a “neutral” rating to an “overweight” rating and set a $116.00 price objective for the company in a research report on Friday, May 1st. Four research analysts have rated the stock with a hold rating and eleven have assigned a buy rating to the stock. Mirati Therapeutics presently has a consensus rating of “Buy” and an average target price of $113.83.

In related news, EVP Isan Chen sold 33,334 shares of the company’s stock in a transaction on Monday, May 11th. The stock was sold at an average price of $105.00, for a total value of $3,500,070.00. Following the sale, the executive vice president now directly owns 72,735 shares of the company’s stock, valued at $7,637,175. The sale was disclosed in a legal filing with the SEC, which is available through the SEC website. Also, major shareholder Ltd. Braslyn sold 600,000 shares of the company’s stock in a transaction on Friday, June 12th. The stock was sold at an average price of $69.00, for a total value of $41,400,000.00. Following the completion of the sale, the insider now directly owns 2,535,966 shares in the company, valued at $174,981,654. The disclosure for this sale can be found here. 4.10% of the stock is owned by corporate insiders.

Shares of Mirati Therapeutics stock opened at $121.31 on Friday. The business has a 50 day moving average of $115.72 and a 200 day moving average of $96.51. Mirati Therapeutics Inc has a 52 week low of $66.01 and a 52 week high of $132.59.

Mirati Therapeutics (NASDAQ:MRTX) last announced its earnings results on Thursday, May 7th. The biotechnology company reported ($2.02) EPS for the quarter, missing analysts’ consensus estimates of ($1.66) by ($0.36). The business had revenue of $0.27 million for the quarter, compared to the consensus estimate of $0.29 million. Mirati Therapeutics had a negative net margin of 10,983.84% and a negative return on equity of 53.25%. The business’s revenue was down 78.5% compared to the same quarter last year. On average, equities analysts predict that Mirati Therapeutics Inc will post -8.7 earnings per share for the current fiscal year.

About Mirati Therapeutics

Mirati Therapeutics, Inc, a clinical-stage oncology company, develops product candidates to address the genetic and immunological promoters of cancer in the United States. The company is involved in developing sitravatinib, a spectrum-selective kinase inhibitor, which is in Phase II clinical for the treatment of non-small cell lung cancer (NCSLC); and in Phase Ib clinical trial to treat NCSLC patients with Casitas B-lineage Lymphoma genetic alterations, as well as KRAS G12C inhibitor program for NSCLC adenocarcinoma patients, colorectal cancer patients, and other cancers.

Recommended Story: Terms to Better Understand Call Options

Want to see what other hedge funds are holding MRTX? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Mirati Therapeutics Inc (NASDAQ:MRTX).

Institutional Ownership by Quarter for Mirati Therapeutics (NASDAQ:MRTX)

Receive News & Ratings for Mirati Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Mirati Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.